164 related articles for article (PubMed ID: 38319075)
1. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating
Zhang X; Wang Y; Li S; Xie F; Yi H
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0154123. PubMed ID: 38319075
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
3. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model.
Wang Y; Liu L; Wu Q; Yin Q; Xie F
Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421304
[TBL] [Abstract][Full Text] [Related]
4. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
[TBL] [Abstract][Full Text] [Related]
5. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
6. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
He X; Liu X; Gong X; Wang L; Chen F
Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
9. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
[TBL] [Abstract][Full Text] [Related]
10. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
[TBL] [Abstract][Full Text] [Related]
15. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
16. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
17. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.
Truong AQ; Dao XC; Vu DH; Nguyen HA; Do THG; Tran NT; Tran NM; Vu NB; Pham HN; Bui VC; Trinh TA; Dang QT; Nguyen GB; Lipman J; Cotta MO; Roberts JA
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0032122. PubMed ID: 36197095
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.
Klastrup V; Thorsted A; Storgaard M; Christensen S; Friberg LE; Öbrink-Hansen K
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284376
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
